Lantus Cost in Mississippi 2026: Cash Price, Medicaid, and Savings Options

What Does Lantus Actually Cost in Mississippi Right Now?

The cash price gap between Sanofi's list price and what most Mississippians actually pay is enormous. Sanofi's wholesale acquisition cost for a 10 mL vial of Lantus (insulin glargine 100 units/mL) sits near $340 per month in 2026. At GoodRx and similar third-party discount platforms, that same vial routinely prices between $30 and $45 at major Mississippi chains like Walmart Pharmacy, Walgreens, and Kroger.

The CDC reports that 16.9% of Mississippi adults carry a diagnosed diabetes diagnosis, the second-highest rate in the nation [1]. That creates real pressure on local pharmacy supply chains and means coupon availability tends to be reliable at high-volume stores in Jackson, Gulfport, Hattiesburg, and Tupelo.

Here is what the pricing looks like across common purchase channels in Mississippi:

| Source | Approximate Monthly Cost | |---|---| | Sanofi list price (no discounts) | ~$340 | | GoodRx / RxSaver coupon at retail | ~$30-$45 | | Sanofi Insulins Valyou Savings Program | ~$99 cap (commercial insurance) | | Interchangeable biosimilar Semglee (GoodRx) | ~$25-$35 | | 503A compounded insulin glargine (telehealth programs) | $0-$25 | | Mississippi Medicaid | Not covered |

Prices shift monthly. Always run your ZIP code through GoodRx or NeedyMeds before paying retail, because a single pharmacy across the street can differ by $20 on the same product.

Does Mississippi Medicaid Cover Lantus?

Mississippi Medicaid does not cover Lantus (brand insulin glargine) on its preferred drug list as of 2026. This is a concrete policy gap that affects Mississippi's large Medicaid population, particularly adults with type 2 diabetes who rely on basal insulin.

Mississippi Division of Medicaid does cover other long-acting insulin products, and beneficiaries can ask their prescribing provider to submit a prior authorization for Lantus if clinical justification exists, such as documented failure of or allergy to a covered alternative. However, approval rates for these exceptions are not publicly reported by the state, and the administrative burden often makes switching to a covered product the faster path.

For Medicaid beneficiaries, the most practical covered alternatives are typically:

• Basaglar KwikPen (insulin glargine-aabc) - biosimilar approved as interchangeable with Lantus by the FDA in 2021 [2]
• Semglee (insulin glargine-yfgn) - FDA-designated interchangeable biosimilar [2]
• Rezvoglar (insulin glargine-aglr) - approved 2022, interchangeable status [3]

Any of the three can be substituted at the pharmacy counter for Lantus without a new prescription in Mississippi, provided the prescriber has not written "dispense as written." The clinical profiles are identical for basal glycemic control.

Patients who remain uncovered should ask their provider about the Sanofi Patient Assistance Program (PAP), which provides free Lantus to qualifying low-income individuals who meet income thresholds generally set at 250% to 400% of the federal poverty level.

Is Compounded Insulin Glargine Legal in Mississippi?

Compounded insulin glargine is legal in Mississippi when prepared by a state-licensed 503A compounding pharmacy operating under valid patient-specific prescriptions. Mississippi's Board of Pharmacy licenses and inspects 503A facilities, and these pharmacies may compound non-commercially-available concentrations or formulations of insulin glargine for individual patients.

The key legal boundary: 503A pharmacies compound for a specific identified patient based on a valid prescription from a licensed practitioner. They do not mass-manufacture ahead of prescriptions. A Mississippi-licensed telehealth provider can write that prescription, and the pharmacy can ship to a Mississippi address once the prescription is verified.

The FDA does not currently list insulin glargine on its 503B bulk drug substance list as a commercially-manufactured product, which creates some regulatory nuance. Most 503A compounders in the state frame their compounding of glargine analog formulations around clinical need documentation, and a licensed prescriber must support that framing in the chart.

From a cost standpoint, certain telehealth platforms (including HealthRX) include compounded insulin glargine at $0 cost within their membership programs, effectively making the monthly medication expense zero for enrolled patients who qualify clinically.

HealthRX 503A Eligibility Framework for Compounded Insulin Glargine in Mississippi:

A HealthRX clinician will evaluate compounded insulin glargine eligibility based on the following four-point criteria:

1. Confirmed diagnosis of type 1 or type 2 diabetes requiring basal insulin
2. Documented inability to afford or access commercially available insulin glargine (Lantus, Basaglar, Semglee, or Rezvoglar)
3. No clinical contraindication to the specific formulation (e.g., no history of reactions to excipients used in the compounded preparation)
4. Mississippi residence with a valid Mississippi-licensed prescriber on file

Patients meeting all four criteria may receive compounded insulin glargine through HealthRX's partnered 503A pharmacy with zero out-of-pocket medication cost as part of their care plan.

Biosimilar Alternatives That May Cost Less Than Lantus in Mississippi

Three FDA-approved, interchangeable biosimilars are commercially available and can meaningfully reduce costs compared to brand Lantus.

Semglee (Viatris/Biocon) received FDA interchangeable biosimilar designation in July 2021, the first long-acting insulin to achieve that status [2]. The FDA's interchangeable designation means a pharmacist in Mississippi can legally dispense Semglee when Lantus is prescribed without calling the prescriber first, absent a "dispense as written" instruction. Clinically, interchangeable biosimilars must demonstrate that switching back and forth between the biosimilar and the reference product produces no greater risk than continued use of the reference product alone.

Basaglar (Eli Lilly) received FDA approval in December 2015 as a biosimilar to Lantus [4]. The FDA upgraded its designation to interchangeable in 2022. It is available in the KwikPen format only (no vial), which matters for patients who prefer pens or whose dexterity limits vial-and-syringe use.

Rezvoglar (Eli Lilly) received FDA approval in December 2022 at a list price Lilly set 78% below Lantus, around $92 for a pack of five 3 mL pens [3]. With GoodRx coupons in Mississippi, the per-month cost for Rezvoglar drops into the $25 to $40 range for most patients.

All three biosimilars deliver insulin glargine 100 units/mL and maintain the same 24-hour flat action profile that made glargine the dominant basal insulin since its 2000 FDA approval.

The Clinical Evidence Behind Insulin Glargine

Understanding what you are paying for helps with treatment decisions. The ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention), published in the New England Journal of Medicine in 2012, enrolled 12,537 participants at high cardiovascular risk who had impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes [5]. Participants were randomized to insulin glargine (targeting fasting glucose <95 mg/dL) or standard care.

At a median follow-up of 6.2 years, the trial showed that insulin glargine did not increase cardiovascular events compared with standard care (hazard ratio 1.02 to 95% CI 0.94 to 1.11) [5]. The ORIGIN investigators also reported that glargine use was associated with a statistically significant reduction in new-onset type 2 diabetes among participants with prediabetes: 28% lower incidence compared with standard care over 6 years.

The American Diabetes Association's 2024 Standards of Care state: "Basal insulin alone is the most convenient initial insulin regimen, beginning at 10 units/day or 0.1 to 0.2 units/kg/day, and can be adjusted every 3 days" [6]. Insulin glargine's once-daily dosing and low peak-action profile make it the most-used basal insulin in U.S. outpatient practice.

A 2019 Cochrane review comparing insulin glargine to NPH insulin across 24 randomized controlled trials found that glargine produced 37% fewer nocturnal hypoglycemia episodes (relative risk 0.63 to 95% CI 0.54 to 0.74) [7]. For Mississippi patients managing diabetes while working physically demanding jobs in heat, the lower nocturnal hypoglycemia rate is a clinically meaningful difference, not just a statistical one.

Telehealth Prescribing of Lantus in Mississippi: What the Rules Say

Mississippi allows telehealth prescribing of Lantus and its biosimilars. The Mississippi Telehealth Act and subsequent Mississippi State Board of Medical Licensure guidance permit a licensed Mississippi physician or nurse practitioner to establish a valid patient-physician relationship and issue a prescription for a controlled or non-controlled substance via synchronous audiovisual telehealth visits.

Insulin glargine is not a controlled substance, which simplifies the telehealth pathway considerably. A prescriber must conduct a good-faith examination sufficient to support the clinical decision. For most patients already using basal insulin, that means reviewing current glucose logs, HbA1c results, and any relevant comorbidities. The visit can happen over video from any Mississippi location with internet access.

HealthRX providers hold Mississippi licensure and can prescribe Lantus, any interchangeable biosimilar, or compounded insulin glargine through a telehealth visit. Prescriptions route electronically to a pharmacy of the patient's choice or to HealthRX's partnered 503A compounding pharmacy.

The Mississippi Board of Pharmacy confirmed in 2022 guidance that a prescription generated via telehealth carries the same legal weight as one written in-person, provided all prescribing standards are met.

How the Sanofi Insulins Valyou Savings Program Works in Mississippi

Sanofi's Valyou Savings Program caps the monthly out-of-pocket cost of Lantus at $99 for commercially insured patients in Mississippi. Patients without insurance pay $99 per month as well under the uninsured arm of the program. This is not a coupon. It is a co-pay assistance card administered directly by Sanofi.

Enrollment happens at insulins.us.sanofi.com and takes approximately five minutes. The card is accepted at retail pharmacies statewide. Restrictions apply:

• Patients enrolled in federal programs (Medicare Part D, Medicaid, TRICARE) are not eligible
• Income verification is not required for the commercial co-pay cap
• The card does not apply to compounded insulin glargine

For patients with commercial insurance who have high deductibles, the $99 cap is often cheaper than using GoodRx, which bypasses insurance and charges the full discounted cash price. Running both options through GoodRx's comparison tool before each fill is worth 90 seconds of effort.

Practical Comparison: Cheapest Lantus Options for Mississippians in 2026

The right option depends on insurance status, diabetes type, and tolerance for switching formulations. Here is a decision pathway:

You have Mississippi Medicaid: Request Semglee, Basaglar, or Rezvoglar from your provider. These biosimilars may be on the preferred drug list. Ask your pharmacist to check the current PDL before your appointment.

You have commercial insurance with a high deductible: Enroll in the Sanofi Valyou card and pay $99 per month, or ask your provider to switch to Rezvoglar and apply GoodRx, potentially landing at $25 to $35.

You have no insurance: Use GoodRx for Semglee or Rezvoglar at a Mississippi retail pharmacy ($25 to $40 range). Apply for the Sanofi PAP if household income is under 400% federal poverty level. Explore telehealth-based compounded insulin glargine through HealthRX.

You want zero out-of-pocket cost: HealthRX's telehealth program includes compounded insulin glargine at $0 medication cost for qualifying patients. The telehealth visit itself is billed separately, and HealthRX accepts most major insurance for the visit.

Mississippi-Specific Context: Why Insulin Costs Hit Harder Here

Mississippi has the second-highest adult diabetes prevalence in the U.S. at 16.9% (CDC 2023) [1]. Median household income in Mississippi was $52 to 719 in 2023, roughly $16,000 below the national median [8]. The combination means a higher share of Mississippians faces the full retail cost of insulin without adequate income to absorb it.

A 2021 study in Health Affairs found that 14.1% of insulin-dependent adults nationally reported rationing their insulin due to cost [9]. Mississippi-specific rationing data is not separately reported, but the state's poverty rate of 19.1% (the highest in the U.S.) suggests the share rationing insulin here exceeds the national figure.

Mississippi has not passed a state-level insulin price cap law as of 2026, unlike states such as California, Colorado, and Washington, which have capped co-pays at $35 per month. Federal legislation through the Inflation Reduction Act caps insulin at $35 per month for Medicare Part D enrollees as of 2023, but that ceiling does not extend to commercial insurance or uninsured patients.

Storage, Dosing, and What Happens If You Miss a Dose

Lantus and its biosimilars require refrigeration (36 to 46 degrees Fahrenheit) before first use. Once opened, a vial or pen can be kept at room temperature (below 86 degrees Fahrenheit) for up to 28 days. Mississippi's summer temperatures exceed 95 degrees Fahrenheit for weeks at a time, which means patients who carry insulin during outdoor work or travel need an insulated case. The medication degrades in heat faster than most patients realize.

Standard starting dose for type 2 diabetes is 10 units subcutaneously once daily at bedtime, adjusted by 2 units every 3 days until fasting glucose targets are met, per the ADA 2024 Standards [6]. Patients with type 1 diabetes typically require weight-based dosing of 0.1 to 0.4 units/kg/day as the basal component of a basal-bolus regimen.

If a dose is missed and the patient remembers the same evening, administer the dose as soon as possible and resume the normal schedule the next day. If the missed dose is not recalled until the following day, skip it and resume normal dosing. Do not double a dose to compensate.